Market Overview

BioLineRx Clarifies Interim Analysis of CLARITY Trial for BL-1020

BioLineRx. (NASDAQ: BLRX) notes that, as previously disclosed, results from
the interim analysis of the Phase II/III CLARITY clinical trial of
BL-1020, a first in class, orally available, GABA-enhanced antipsychotic
for the treatment of schizophrenia, are expected to be reported during
the week of March 18, 2013. The CLARITY trial is a randomized,
double-blind trial to examine acute (6 weeks) and long-term (24 weeks)
cognitive and antipsychotic efficacy, safety and tolerability of BL-1020
on patients with acute schizophrenia. The interim analysis will be
performed on data of approximately 235 randomized patients from 27 sites
in Romania and India.

The interim analysis will be performed by a fully independent, external

See full press release

Posted-In: News Guidance Contracts Management Global

 

Related Articles (BLRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional